Ascendis Pharma A/S $ASND Shares Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. reduced its stake in Ascendis Pharma A/S by 13.3%, leaving it with 242,761 shares valued at approximately $37.8 million.
• The company recently reported an earnings per share (EPS) of ($0.93), beating estimates by $0.49 and achieving $216.28 million in revenue for the quarter.
• Wall Street analysts maintain a consensus “Buy” rating for the stock, with a notable price target range of $203.00 to $307.00.

Candriam S.C.A. trimmed its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 13.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 242,761 shares of the biotechnology company's stock after selling 37,393 shares during the period. Candriam S.C.A. owned about 0.40% of Ascendis Pharma A/S worth $37,837,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth $28,000. Brooklyn Investment Group lifted its position in shares of Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 273 shares in the last quarter. Quarry LP acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth $96,000. Tower Research Capital LLC TRC lifted its position in shares of Ascendis Pharma A/S by 195.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after purchasing an additional 664 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth $174,000.

Wall Street Analyst Weigh In

ASND has been the topic of a number of recent research reports. Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a research report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 target price on the stock. Cantor Fitzgerald lifted their price target on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. UBS Group restated a "buy" rating and issued a $307.00 price target (up previously from $306.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Oppenheimer restated an "outperform" rating and issued a $224.00 price target (up previously from $215.00) on shares of Ascendis Pharma A/S in a research note on Friday, June 13th. Finally, Royal Bank Of Canada lifted their price target on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Fifteen research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $243.36.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $194.62 on Wednesday. The company has a 50-day simple moving average of $176.87 and a 200-day simple moving average of $162.30. The firm has a market capitalization of $11.91 billion, a P/E ratio of -37.72 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. As a group, sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.